Drug intelligence / Profile preview

CM536

Development stage: Preclinical
Lead developer: Keymed Biosciences

Overview

CM536 is an investigational drug candidate initially developed by Keymed Biosciences (Keymed Biomedical Technology, Chengdu). As of mid-2025, it has reached the IND (Investigational New Drug) application stage and has not yet entered clinical trials or received regulatory approval. In July 2024, Keymed granted Belenos exclusive global rights to develop, manufacture, and commercialize CM536. Specific details regarding its mechanism of action, molecular target(s), modality (e.g., small molecule or biologic), and therapeutic indication have not been publicly disclosed as of June 2025[1][2][3][4].

Beyond the preview

Go deeper on CM536.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CM536.

Explore the full profile